Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 March 2022

The Dean of the Faculty of Law invites staff and interested individuals to attend the inaugural lecture of Prof Ulrike Kistner, Department of Public Law, titled The ‘person’ in question – legally, grammatically, philosophically.

Date: 17 March 2022
Time: 17:30
Venue: Equitas Auditorium

To attend the lecture, please RSVP to Refilwe Majola at MajolaRRM@ufs.ac.za

More about the speaker:

Prof Kistner has held teaching positions in Comparative Literature at Wits University, Modern European Languages at UNISA, and Philosophy at the University of Pretoria. She is currently working at intersections between political philosophy, social theory, jurisprudence, and psychoanalytic theory.

Abstract:

A major shift has been noted in constitutionalism and human rights frameworks – from human and civil rights to principles centred on ‘personhood’ and ‘dignity’. This shift calls for closer historical-critical investigation of the status of ‘person’. Roberto Esposito directs this inquiry to a philosophical grammar of the impersonal third person.

My contribution to this inquiry sets in with a probing of Esposito’s propositions, considering the post-apartheid elevation of ‘person’ in constitutionalism and philosophical elaborations of communitarianism. To the extent that the concept of ‘ubuntu’ is embedded in a linguistic ontology developed by Kinyarwanda, my argument will navigate between Rwanda and South Africa in the mid-1990s, and between juridical, moral-philosophical, linguistic, and Africanist notions of ‘ubuntu’ and corresponding claims on African philosophy.

The radical questioning of ethnolinguistic tenets on the part of some African philosophers brings me back to the philosophical grammar of the third person which, far from being confined to study old grammar books, opens alternatives to ethnophilosophical approaches to the ‘person’ in question. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept